All In Biotech

Drug Trial Radar · NCT03645980

DKN-01 Inhibition in Advanced Liver Cancer

A Phase I/II Multicenter, Open-label Study of DKN-01 to Investigate the Anti-tumor Activity and Safety of DKN-01 in Patients With Hepatocellular Carcinoma and WNT Signaling Alterations

Last checked: Nov 19, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

70

Planned (sponsor's estimate)

Start

Oct 10, 2018

Primary completion

Aug 31, 2021

Study completion Aug 31, 2022

Sponsor

Lead sponsor
Johannes Gutenberg University MainzAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Leap Therapeutics, Inc.
First posted
Aug 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a prospective, open label, single arm oncological phase I/II trial in patients with hepatocellular carcinoma and WNT signaling alterations. The trial consists of two parts: Part A is a phase I study investigating the safety of DKN-01 administered as mono- as well as combination therapy with sorafenib in a 2 step dose escalation.Part B is a phase II study to investigate the anti-tumor activity and safety of DKN-01 in patients with advanced HCC. DKN-01 is administered at the recommend phase II dose (RP2D) for monotherapy and at the recommend phase II dose for combination therapy established in Part A.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • DKN-01 300 mgDrug

    DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.

  • DKN-01 600 mgDrug

    DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.

  • SorafenibDrug

    For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Adverse EventsTime frame: assessment period is 2 cycles for monotherapy (each cycle is 28 days)
  2. Phase I: Adverse EventsTime frame: assessment period is 2 cycles for combination therapy (each cycle is 28 days)
  3. Phase II: Time to progression (TTP2)Time frame: time from the first DKN-01 intake until PD2, assessed up to 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Köln

    Cologne, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Med. Hochschule Hannover

    Hanover, Germany · Recruiting

  • Universitätsklinikum Schleswig Holstein Campus Lübeck

    Lübeck, Germany · Recruiting

  • Universitätsmedizin Mainz, I. Med. Klinik und Poliklinik

    Mainz, Germany · Recruiting

  • II. Medizinische Universitätsklinik Gastroenterologie, Hepatologie, Infektiologie

    Mannheim, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.